Publish date:

FDA OKs Bristol-Myers' Ixempra

The therapy is approved to treat patients with metastatic or locally advanced breast cancer.

Bristol-Myers Squibb

(BMY) - Get Report

said Tuesday after the market close that the Food and Drug Administration approved its Ixempra as a monotherapy to treat patients with metastatic or locally advanced breast cancer.

The FDA approved the drug as a monotherapy for patients whose tumors are resistant or unresponsive to anthracyclines or taxanes, as a combination with capecitabine for patients resistant to anthracycline and taxane, or for those unable to take anthracycline anymore. Bristol-Myers Squibb said it expects Ixempra to be available in days.

TheStreet Recommends

Shares closed at $29.24, but rose 2.6% to $30 in recent after-hours trading.